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Abstract 
Healthcare regulators are directing attention to the pharmaceutical supply chain with the passage of 
the Drug Quality and Security Act (DQSA) and the Drug Supply Chain Security Act (DSCSA). Adoption 
of Radio-Frequency Identification (RFID) technology has the ability to improve compliance, reduce costs, 
and improve safety in the supply chain but its implementation has been limited; primarily because of 
hardware and tag costs. The purpose of this research study was to analyze the benefits to the 
pharmaceutical industry and healthcare system of the adoption of RFID technology as a result of newly 
implemented supply chain regulations. The methodology was a review following the steps of a systematic 
review with a total of 96 sources used. With the DSCSA, pharmaceutical companies must track and trace 
prescription drugs across the supply chain, and RFID can resolve many track-and-trace issues with 
manufacturer control of data. The practical implication of this study is that pharmaceutical companies 
must continue to have the potential to increase revenues, decrease associated costs, and increase 
compliance with new FDA regulations with RFID. Still, challenges related to regulatory statute wording, 
implementation of two-dimensional barcode technology, and the variety of interfaces within the 
pharmaceutical supply chain have delayed adoption and its full implementation.  
Keywords: costs, Drug Quality and Security Act, Drug Supply Chain Security Act, pharmaceuticals, 
radio-frequency identification, RFID 
Introduction 
Healthcare expenditures in the United States neared $2.6 trillion or 17.9 percent of the gross domestic 
product (GDP) in 2012.1, 2 Healthcare expenditures are much higher in the United States than in other 
western countries such as the United Kingdom (9.4 percent), France (11.7 percent), and Canada (10.9 
percent). In the United States, it has been forecasted that healthcare expenditures, if they continue on their 
current track, may exceed 20 to 25 percent of GDP by 2020.3 This cost shows the need for innovation that 
can drive the United States toward a more cost-efficient healthcare system. Currently, prescription drug 
costs total approximately $250 billion and are the third leading healthcare expense.4 To decrease total 
overall drug spending, which is a significant portion of the total overall healthcare expenditures, it is 
necessary to reduce expenditures in the pharmaceutical industry, such as those that result from process 
inefficiencies and lack of patient safety.5 
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Radio-frequency identification (RFID) can help provide a quick way to retrieve information, track 
pharmaceuticals or items in the supply chain, and help avoid the costs associated with counterfeit or 
adulterated medications.6 RFID is a technology that uses radio waves to automatically track people or 
objects and associate programmed information with these people or objects. This system is composed of a 
tag, a reader, an antenna, and software. The tag is placed on an individual object, which allows for unique 
identification. When an RFID-tagged item is sent through a reader’s field of view, a distinct data code is 
transmitted. The antenna transfers the information from the tag to the reader or vice versa.7 RFID tags are 
classified as active or passive.8 Active tags are battery powered and transmit a signal over 100 feet at 
predetermined intervals and in healthcare are commonly used for the tracking of equipment or bins. 
Passive tags are activated by an outside power source when they are swiped within the field of a reader. 
The tags can be read-only or read-write. Read-only tags transmit data from the RFID reader to the 
database, whereas read-write tags can retrieve or send data.9 
RFID technology was invented in 1948 but was not applied commercially until the 1990s, when 
standards for the technology were developed. Between 2000 and 2010, wide-scale adoption of RFID 
technology began.10 Large retail companies were leading RFID adopters. In 2003, Wal-Mart began 
implementation of a plan that was supposed to result in all suppliers using RFID tagging on products 
distributed by 2006. The technology was expected to increase inventory visibility and management. Initial 
phases of the plan showed a 16 percent reduction in out-of-stock items. As the Wal-Mart implementation 
continued, supplier compliance diminished, largely because of suppliers not wanting to implement 
multiple systems, variances in state regulations, and comparatively high tag costs compared to the costs of 
linear and matrix bar codes, which challenged the success of the plan. Wal-Mart’s implementation of 
RFID gained groundbreaking recognition and served as an example for other companies that desired to 
implement the technology, but the technology never quite caught on with pharmaceutical manufacturers.11 
Although RFID is a more reliable technology, the use of bar coding (especially two-dimensional [2D] 
bar coding) has been a more widely accepted form of electronic identification in the pharmaceutical 
industry.12 RFID, however, has many advantages over linear 2D bar coding. A barcode on a 
pharmaceutical bottle contains a stock-keeping unit (SKU) representing the national drug code (NDC) 
and may contain other information such as expiration date, package size, and lot number, but it does not 
change without being replaced with a new sticker or package requiring a direct line of sight. In addition, 
the barcode is easily counterfeited, whereas an RFID tag is almost impossible to counterfeit. An RFID tag 
contains an electronic product code, which is a unique identifier for each item or serial number (no two 
items are identical). This identifier can be associated with all kinds of information, such as specific dates 
on which it was held in a warehouse, transferred to another supplier, or returned to the manufacturer. 
RFID eliminates the need for a direct line of sight to the tag. While traditional linear 2D barcodes and 
matrix barcodes can contain a lot of information, they are still limited in the total amount of information 
stored and must be replaced if changes are made. The major limitations of barcodes are that they are 
printed, so a new barcode has to be applied to the product to update the product, and they also require a 
line of sight. In contrast, RFID tags offer track-and-trace technology that can be programed by the 
manufacturer and secured for information governance (read-only tags) and is virtually impossible to copy 
or counterfeit, which is vital for the drug pedigree.13, 14 They also can come in other forms including read-
write, write-once, and read-many, which can be valuable if information needs to be adjusted or 
circumstances vary. Exposure to the outdoors, package tears, external markings, stickers, chemicals, 
moisture and extreme temperatures renders traditional 2D barcodes unreadable, thus requiring frequent 
replacement and opening the door to potential errors. RFID tags are more resistant to environmental 
conditions and are also embedded within the product by the manufacturer, decreasing replacement costs.15 
Limitations of RFID technology may include liquid or compounded dosage forms, where tags may not 
work well, and the fact that there are multiple frequencies in use with RFID. 
Read times of less than 100 milliseconds allow large numbers of RFID tags to be scanned at once.16 
Barcodes are programmed for specific products and cannot be altered, whereas RFID tags are rewritable 
and reusable up to thousands of times. They have been successfully used by pharmacy automation 
companies and warehouses in supply chain applications with well-documented return on investment 
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(ROI). In addition, many components of RFID have advantages over bar coding technology that can 
improve the effectiveness and security of the supply chain industry.17 
Automatic data collection is necessary in the pharmaceutical industry to ensure patient safety and 
decrease expenses.18 The cutting-edge technology of RFID has the potential to decrease the immense 
costs in the pharmaceutical industry by augmenting patient safety, ensuring visibility of products, and 
simplifying management of inventory.19 In addition, it has become a much more affordable option as the 
technology has matured, with a passive tag cost of $0.10 to $0.50 per tag.20 
The purpose of this research study was to analyze the benefits to the pharmaceutical industry and 
healthcare system of the adoption of RFID technology as a result of newly implemented supply chain 
regulations. 
Methodology 
The research approach of this review followed the steps and research framework utilized by Yao, 
Chu, and Li (2010).21 Figure 1 displays the process of RFID adoption in healthcare. To research how 
RFID systems can help improve the pharmaceutical process, the first requirement is to identify the 
existing benefits of its adoption in the US pharmaceutical supply chain and problems with RFID 
adoption. Solutions can then be identified to resolve or partially resolve these challenges. The use of the 
conceptual framework of this study was appropriate because it addressed the process of adopting and 
utilizing any health information technology (HIT) system. The technology adoption process works much 
like any project development system in that it is circular; it starts with problems and issues, and needs are 
determined before a solution is created and initialized. In this case, the solution is the utilization of an 
RFID system. After the RFID system has been adopted, the process includes an assessment of the benefits 
of and barriers to the use of RFID, and the process starts over so that the barriers can be addressed and the 
benefits assessed (see Figure 1). The use of this conceptual framework in the present study is applicable 
because the focus is to show how new technologies can be applied in healthcare settings. In addition, this 
approach has been successfully replicated in previous studies, supporting its internal validity.22,23 
The methodology for the examination of the benefits of and barriers to RFID adoption followed the 
basic principles of a systematic review. The study was conducted in three stages: (1) identifying the 
literature and collecting the data, (2) analyzing and evaluating the literature found, and (3) categorizing 
the literature. 
Step 1: Literature Identification and Collection 
The methodology used for this review consisted of a literature review and research of case studies 
following the basic principles of a systematic search. The electronic databases EBSCOhost, Academic 
Search Premier, CINAHL, Business Source Premier, Iowa Drug Information Service (IDIS), and 
MEDLINE were searched for the terms RFID AND pharmaceutical industry OR pharmacy management 
OR pharmacy OR medicine OR pharmaceutical. Reputable websites including Kaiser Permanente, RFID 
Incorporated, RFID Journal, and other reliable healthcare and technology websites were also used. 
Step 2: Literature Analysis 
Literature was selected for review on the basis of benefits of and barriers to RFID implementation. 
Inclusion and exclusion criteria were as follows: Only articles published from 2006 to 2015 were utilized 
to keep this review current. The search was restricted to sources attainable as full texts and written in the 
English language. Only primary and secondary data from articles, reports, reviews, and research studies 
written in the United States were included in this research study.  
Step 3: Literature Categorization  
Abstracts of the articles were reviewed first to determine the relevancy of the data to the study. 
Citations and abstracts identified by the search were also assessed in order to identify relevant references. 
If academic articles and studies were found to be appropriate from the abstract reviews, the full articles 
were analyzed and categories were generated on the basis of the findings. The literature review generated 
96 sources that were assessed for information pertaining to this research project, and 62 were used in the 
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Results section. The literature search was conducted by M.N and C.K., MT and was validated by A.C., 
who acted as a second reader and also double-checked that the references met the inclusion criteria of the 
research study. The results were organized following the conceptual framework, which employed 
subcategories including the cost of counterfeit drugs to the pharmaceutical industry and RFID as a 
solution (20 references), implications of RFID for patient safety in pharmaceuticals (20 references), and 
RFID and improvement of efficiency in pharmaceuticals and the supply chain (22 references) 
Results 
The Cost of Counterfeit Drugs to the Pharmaceutical Industry and RFID as a Solution 
Counterfeit drugs are a growing problem in the pharmaceutical supply chain worldwide (see Table 1). 
The World Health Organization (WHO) has stated that about 10 percent of the pharmaceutical trade 
globally has been confirmed counterfeit.24 The global market is expected to see a 90 percent rise in the 
amount of counterfeit drugs from 2014 to 2019, and it has been reported that about $75 billion annually 
will be spent on purchasing and dealing with counterfeit products.25 In addition, legitimate manufacturers 
lose $32 billion yearly in revenue because of fraudulent drug activity.26 
Because of the complexity of the pharmaceutical distribution infrastructure, less than 1 percent of the 
four million pharmaceuticals shipped via the US mail system are screened by the Food and Drug 
Administration (FDA).27 This lack of screening has resulted in up to an estimated 10 percent of 
pharmaceutical packages containing unauthorized drugs.28 It is also widely believed that RFID 
implementation is the most promising technology to quickly combat counterfeit drugs and ensure 
compliance with new track-and-trace regulations, especially because the information can be governed by 
the manufacturer.29 (See Table 1.) Other technologies under development could replace this technology in 
the future. However, technologies beyond RFID systems are not ready for full-scale implementation 
across the pharmaceutical supply chain. 
According to Bacheldor (2007),30 only 12 percent of pharmaceutical companies were adopting RFID, 
16 percent were evaluating the benefits, 10 percent were unaware of the technology, and 40 percent were 
aware but not evaluating it when the Wal-Mart program gained momentum. For varied reasons, the 
pharmaceutical industry has been slow to adopt RFID technology. One of the biggest barriers to full scale 
RFID in the Pharma supply chain has been the pharmaceutical companies’ perception that the ROI is not 
achieved in the short term. Perception has been that RFID is an expensive long-term investment with only 
partial adoption with achievement of ROI only being achieved over time. There has historically been a 
significant expense to complete software and hardware implementation with a significant ongoing cost 
tag post implementation.31 Attaran (2012)32reported that the implementation of a complete RFID system, 
in a large manufacturing company, can cost $10 to $25 million. Some companies may see the investment 
as a financial risk, but some studies have shown that the ROI may be tenfold, and this knowledge may 
influence healthcare institutions’ decision to implement RFID.33 For example, after RFID was 
implemented at RiteCare Pharmacy, the cost of warehouse inventory was reduced by 60 percent, order 
fulfillment time was cut in half, and salary expenses were decreased. Accuracy, scalability, productivity, 
and customer satisfaction increased, proving the potential for a positive ROI with RFID implementation.34 
Another challenge of RFID is that the technology is scalable across the US pharmaceutical supply 
chain but has yet to be fully implemented and prior to the DSCSA was covered under individual state 
regulations. That chain is composed of multiple segments, each of which would have to have the 
technology implemented to fully utilize RFID to its potential.35 These segments include manufacturers 
and their affiliates, drug wholesale distributors, secondary or gray-market suppliers or intermediaries, 
retail pharmacies, hospital pharmacies, specialty pharmacies, physician offices and clinics, dental offices, 
and companies that handle pharmaceutical returns.36 The complexity of the healthcare distribution system 
and its many different processes and systems has complicated the full utilization of RFID. 
RFID has allowed the creation of electronic drug pedigrees (e-pedigrees) instead of the current 
manual ones. E-pedigrees are auditable electronic documents that provide the distribution history of a 
drug, including the dates of sales, purchases, or trades as well as the parties associated with each 
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transaction.37 E-pedigrees help to ensure authenticity of the medication through the supply chain. Also, 
this feature seems to be one of the most promising areas of use for the RFID technology, and the new 
rules seem to have generated additional interest in the implementation of RFID. Pharmaceutical pedigrees 
have historically been and continue to be recorded on paper, allowing room for gaps, forgery, and drug 
counterfeiting and creating storage and retrieval challenges.38 Unlike paper pedigrees, e-pedigrees contain 
technology to prevent tampering, thereby reducing the amount of drugs counterfeited and the revenue 
losses experienced by pharmaceutical companies.39 
One barrier that has slowed implementation of RFID has been the multiple regulatory processes in a 
complex system. Previously there were no federal or global standards that guided the pharmaceutical 
industry on standardization of drug pedigrees. In addition, the worldwide pharmaceutical supply chain 
offers multiple opportunities for a product to become contaminated, diverted, or adulterated. At the state 
level, numerous attempts have been made to tighten licensing and regulations of the pharmaceutical 
supply chain. These attempts include, but are not limited to, track-and-trace legislation put into place in 
California several years ago. Even with tight state regulations, counterfeiting and product alteration 
remains at an all-time high worldwide. Newly passed federal regulations attempt to streamline and 
standardize a very complex system and to provide guidance on this issue.  
On November 27, 2013, President Obama signed the Drug Quality and Security Act (DQSA), which 
became law, amending the Federal Food, Drug, and Cosmetic Act.40,41 Title II of the DQSA, the Drug 
Supply Chain Security Act (DSCSA), sets forth new definitions and requirements related to product 
tracking and tracing of prescription drugs, including the work of drug wholesale distributors and third-
party logistics providers.41 These rules replace the previous differing state rules and regulations 
concerning the pharmaceutical supply chain and standardize the US market’s track-and-trace rules. The 
DSCSA outlines critical steps to build an interoperable electronic system by November 27, 2023, which 
will identify and trace certain prescription drugs as they are distributed in the United States, facilitating 
the exchange of information at the individual package level about where the drug has been in the supply 
chain.42 This new system will enhance the FDA’s ability to help protect US consumers by improving 
detection and removal of potentially dangerous products from the pharmaceutical distribution supply 
chain.  
New supply chain regulations will require several key items in the future. Both manufacturers and 
repackagers will need to put a unique product identifier on prescription drug products, starting with the lot 
level and eventually at the package level, including either an electronically readable barcode, RFID tag, or 
other method of identification. Systems to identify products must be implemented and standardized. 
Regulations also require a process to quarantine or segregate inventory that is suspected to be 
counterfeit.43 Products must also have product tracing throughout the drug supply chain identifying each 
time a product is handled. New track-and-trace rules for manufacturers and repackagers went into effect 
on January 1, 2015. Beginning July 1, 2015, the drug supply chain began providing information about 
each time a product is handled or sold in the US market, including lot number, transaction history, and a 
transaction statement. As key elements are phased in over the next several years, the opportunity to 
maximize the use of RFID to meet these guidelines becomes more affordable and more appealing to 
pharmaceutical manufacturers. With new regulations in place, there now seems to be momentum to make 
the change from paper pedigrees to e-pedigrees, and RFID can help accomplish this task. 
Implications of RFID for Patient Safety in Pharmaceuticals 
A medication error is an avoidable event that leads to inappropriate medication use or patient harm. 
An estimated 1.5 million medication errors occur annually in the United States.44 Medication errors cause 
up to 200,000 injuries or deaths in the United States annually.45 These errors can occur during 
prescription writing or filling, order communication, product labeling, packaging, compounding, 
dispensing, distribution, and administration.46 RFID technology, through automatic identification, can 
detect and avert errors during medication administration and has penetrated through the healthcare 
system.47 Use of RFID has been estimated to decrease this risk across the healthcare continuum in a 
variety of ways.48 
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In 2008, it was estimated that the cost of medical errors equaled $17.1 billion. This amount was also 
72 percent of the $2.391 trillion that was spent on healthcare in 2008.49 To prevent medication errors, five 
“Rs” have historically been assessed prior to administration of medications, including right medication, 
right patient, right time, right dosage, and right route. Implementation of RFID decreases the risk of a 
medication error by ensuring four of these five items.50 RFID tags on medication bins, the patient’s 
wristband, and the provider’s identification badge serve to reduce medication errors. RFID technology 
has also led to more accurate assessment of patient allergies and drug interactions, further decreasing the 
risk of adverse events.51  
RFID tags in the pharmaceutical industry have helped to reduce the adverse effects associated with 
patient noncompliance.52 With increased demands, physicians spend an average of only six to eight 
minutes with each patient, leaving limited time to explain the medication regimen, purpose, and 
detrimental effects of noncompliance.53  
Patient safety has improved as a result of pharmacies’ ability to efficiently manage expired and 
recalled drugs. 54 Recalls have been a growing concern, increasing 309 percent from 2008 to 2009 and 
continuing to grow as medication suppliers become more global in nature.55 RFID can track the location 
of recalled medication within the supply chain.56 RFID tags combined with “smart shelves,” automated 
cabinet or robotic dispensing, and other inventory management tools help to identify drugs that have been 
recalled by reading lot numbers.57 The patient or pharmacy can then be contacted and informed of the 
recall.57 
A growing threat to international health is counterfeit drugs, which have been associated with 
approximately 1 to 10 percent of the drug supply in developed nations, 10 to 30 percent of the drug 
supply in developing nations, and more than 50 percent of the drug supply in certain Asian and African 
markets.58-61 This threat has created an urgent need for tracking of medications from the manufacturer to 
the patient.62 The World Health Organization (WHO) has estimated that 30 percent of the drugs in Asia, 
Africa, and Latin America are counterfeit. This has a direct effect on the United States because 40 percent 
of drugs are from overseas, and 80 percent of the ingredients are imported.63 E-pedigrees protect 
consumers from contaminated and counterfeit drugs by verifying the authenticity of the drug before it 
reaches the consumer.64  
Medication errors have created an added financial burden on the healthcare system because they are 
classified as “never events” and are not reimbursed by the Centers for Medicare and Medicaid Services 
(CMS).65 The malpractice claims that partially stem from these errors cost $55.6 billion in 2010.66 Using 
RFID technologies to improve patient safety and satisfaction can help to decrease malpractice claims, 
reduce the number of dispensing errors, and help to control the rising costs of healthcare.67  
Another major concern that has arisen among pharmaceutical companies and patients alike is the fear 
of invasion of patient privacy.68 RFID tags are reusable and can be read from a distance through various 
materials. The obtainment of private information by unauthorized users raises the question of whether 
tags should be capable of authenticating the reader. It is also important to determine if the tags should be 
decommissioned to protect patient privacy.69 The process of protecting patient privacy has been called 
“privacy by design” or “Architected IT.” and has shown that privacy concerns are valid, but it has been 
noted that RFID helps to protect patient privacy because of the special devices necessary to read the 
tags.70 
RFID and Improvement of Efficiency in Pharmaceuticals and Supply Chain 
Approximately $11 billion healthcare dollars were wasted in 2008 because of the lack of supply 
management structure.71 Many of the inefficiencies in the pharmaceutical industry originate from the 
inventory management of recalled, expired, overstocked, and out-of-stock drugs. RFID uses precise 
automated inventory management to help overcome these inefficiencies.72 
Drug companies lost more than $2.7 billion in 2010 because of product recall logistics and returns 
from drug expiring and overstocking.73 In 2006, Barua, Mani, and Whinston74 estimated that 
pharmaceutical stock-outs cost an estimated $3.14 billion. RFID makes pharmaceutical ordering more 
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precise by providing real-time current inventory, allowing maintenance of smaller stocks and thereby 
reducing the amount of drugs that expire and are wasted.75 With the use of RFID, pharmaceutical 
companies can manage as much as 40 percent of their inventory more efficiently, potentially saving large 
manufacturers $17 million to $55 million annually.76 The decrease in pharmaceutical costs and overall 
healthcare savings is beneficial to all US healthcare consumers.77 
The time and funds spent tracking and replacing expensive equipment are a source of significant costs 
for pharmacies.78 Historically, pharmacies have used manual processes to manage their assets, resulting in 
high labor costs, opportunities for diversion, lost time, and the possibility of human error. RFID tracking 
can increase efficiency and reduce costs related to asset management.79 RFID access points set up 
throughout facilities provide the exact location of mobile RFID-tagged items.80 RFID has also helped 
pharmacies improve asset utilization by reducing expenses related to lost and stolen equipment.81 
The many methods of improved efficiency have served to reduce labor costs for pharmaceutical 
companies.82 Also the benefits of RFID in terms of cost reduction can be seen in hospitals, as in the 
example of Mission Hospital in California. After the hospital’s implementation of RFID asset-tracking 
technology, the rate of lost and stolen devices decreased from 13.8 percent to none, resulting in annual 
cost savings of $150,000 to $200,000.83 
Inventory visibility is vital when it comes to supply chain management because companies can 
receive information about their inventory that will improve the management of their assets.84 Some 
hospital administrators are also recognizing this fact, and this low-cost system is improving the quality of 
care in patients. In 2014 the Texas Health Alliance saved more than $65,000 every month by using RFID 
at the Texas Health Harris Methodist Hospital Alliance in Fort Worth.85 
After the fall of 2012, when 750 individuals were sickened and the deaths of 60 people were caused 
by contaminated drugs, both houses of Congress decided to strengthen the FDA’s ability to support the 
regulation of large drug companies. This regulation was implemented with the DQSA, which focused on 
issues of drug compounding and the drug supply chain.86 In order to make the drug supply chain more 
secure, the DSCSA was passed to ensure safety with product identification, tracing, and verification, as 
well as detection of and response to problems.87 
Discussion 
The purpose of this research study was to analyze the benefits to the pharmaceutical industry and 
healthcare system of the adoption of RFID technology as a result of newly implemented supply chain 
regulations. The findings of this study suggest that implementation of RFID technology could help reduce 
pharmaceutical costs related to counterfeiting, patient safety, and inefficiencies, and result in greater 
compliance with new track-and-trace regulations.  
It has been established that RFID can help to decrease counterfeiting, improve patient safety, and 
increase pharmaceutical management efficiency, all of which have the potential to decrease 
pharmaceutical costs. In addition, medication errors can be significantly be reduced. However, 
implementation of RFID alone is not sufficient. The RFID technology must be integrated into the 
company’s existing workflow and information technology infrastructure. In addition, the RFID 
technology implemented by a company must be interoperable with the RFID systems of partner 
companies, and manufacturers want a standard across the world, not multiple systems and varying or 
inconsistent regulations and standards.  
The findings of this study suggest that adoption and use of RFID technology in the pharmaceutical 
industry can lead to decreased costs and increased supply chain security, resulting in improved patient 
safety, efficient supply chain management, and reduction in counterfeiting. With the implementation of 
the new regulations through the DQSA, full RFID implementation across the pharmaceutical supply chain 
will help reduce the number of medication errors, reduce the number of counterfeit drugs making it into 
the supply chain, and increase supply chain security by increasing compliance with the federal 
requirements.  
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A challenge with RFID implementation is that the type of RFID tag that can be used often depends on 
the item that is labeled. Errors have been noted in reading RFID tags on liquid items due to attenuation of 
RFID signals passing through liquids.88,89 This fact can require a line of sight to the RFID tag, largely 
eliminating the advantage of RFID in these circumstances. 
A lack of updated quantitative research on the financial benefits of RFID implementation for the 
pharmaceutical industry was one limitation of the study. There is also limited research on the extent of 
pharmaceutical companies’ implementation of this technology. Of the research found, many of the 
websites and blogs were not peer-reviewed and could contain biased or inaccurate data. Minimal research 
was found on how RFID can improve patient safety and pharmaceutical supply chain management; 
therefore, more research is needed in these areas. Also, further research, such as a rigorous systematic 
review and/or a meta-analysis, should be conducted to assess future outcomes of RFID implementation in 
the pharmaceutical industry.  
The practical implication of this study is that pharmaceutical companies have the potential to increase 
the cost effectiveness of supply chain and asset management through implementation of RFID 
technology. However, to obtain the maximum results, the implementation must include a well-devised 
plan that is adequately executed to ensure interoperability with the manufacturer’s information technology 
(IT) infrastructure and customers’ and partners’ current HIT infrastructure.  
Conclusion 
New regulations on the pharmaceutical supply chain, healthcare reform, and changes in payment to a 
performance-based system will demand that the pharmaceutical industry provide pharmaceuticals in an 
efficient, secure, and cost-effective manner, which can be aided by the utilization of RFID. 
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Table 1 
 
Examples of Counterfeit Drug Issues Threatening Health and Safety Worldwide That Are 
Potentially Preventable with Radio-Frequency Identification (RFID) and Widespread 
Implementation of e-Pedigree Technology 
 
Drug Name Issue 
Procrit (epoetin alpha)90 Procrit is a drug used in to treat anemia in HIV, kidney 
failure, and cancer treatments. Counterfeit product that 
made it into the US market was actually bacteria-
contaminated water or diluted product. 
  
Cardiovascular medications like heparin90,91 Heparin is an anticoagulant also known as a “blood 
thinner.” Product was contaminated with oversulfated 
chrondroitin sulfate somewhere in the supply chain in 
China. Responsible for 152 adverse events in 113 
patients in 13 states.  
Biaxin (clarithromycin) and other 
antibiotics90,91 
Product with no active ingredients (placebos) made its 
way into the US supply chain. These products could 
make patients sicker by not treating an infection. 
Products may also be tainted by heavy metals or other 
dangerous ingredients. 
Lipitor (atorvastatin)90 
 
Large quantity of counterfeit product made its way into 
the US pharmaceutical supply chain, resulting in a large 
recall with more than 200,000 units recalled. 
Zerit (stavudine)90,91 HIV medication that had counterfeit and misbranded 
products (e.g., 40 mg labeled as 30 mg) made its way 
into the US market. Problems with HIV drugs subject 
patients to dangers such as lack of treatment and 
exposure to toxic compounds. 
Multiple drugs in Africa including drugs to 
treat HIV, cardiovascular drugs, and drugs 
used to treat tuberculosis91,92 
WHO reports that many counterfeit items have been 
used in Africa, and some nations may have up to 40 
percent of their drug supply consisting of counterfeits. 
Cialis (tadalafil), Viagra (sildenafil), Levitra 
(vardenafil)91,93 
 
 
Counterfeit versions of erectile dysfunction drugs have 
been found in the mail on the way to US consumers. 
Products have been noted to contain any number of 
hidden poisons such as road paint, antifreeze, or an 
undeclared and unapproved medication such as 
Sibutramine.  
Botox (Onabotulinumtoxin A)94.96 Product used for cosmetic purposes and to treat 
migraines. With one batch, four victims were 
hospitalized with severe botulism poisoning. The 
paralysis was temporary as a result of being injected 
with potent, unapproved botulinum toxin.  
Antineoplastic drugs91,95 Fake cancer drugs have been found in Israel, China, and 
the United States. Multiple products were affected, 
including Avastin vials containing no real drug. 
Abbreviations: HIV, human immunodeficiency virus; WHO, World Health Organization. 
